Popular weight loss drug could cause sudden blindness – EU's health watchdog
Following a comprehensive safety review, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) determined that non-arteritic anterior ischemic optic neuropathy (NAION) should be listed as a 'very rare' side effect of semaglutide – the main component of weight-loss and anti-diabetic drugs produced by Novo Nordisk.
The EMA's review, initiated in January 2025, analyzed data from clinical trials, post-marketing surveillance, and medical literature. Findings suggest that adults with type 2 diabetes taking semaglutide have approximately twice the risk of developing NAION compared to those not on the medication.
On Friday, the EU's health watchdog recommended updating the product information for semaglutide-containing medicines to include NAION as a potential side effect. The 'very rare' classification indicates that the condition may affect up to 1 in 10,000 users.
NAION is the second most common cause of optic nerve-related blindness after glaucoma. Patients experiencing sudden vision loss or rapidly worsening eyesight while on semaglutide are advised to seek immediate medical attention and discontinue use if NAION is diagnosed.
The Denmark-based company Novo Nordisk owns the patent on semaglutide, a GLP-1 receptor agonist used for managing type 2 diabetes and obesity. It functions by enhancing insulin secretion and promoting a feeling of fullness, thereby aiding in blood sugar control and weight management.
A recent study also indicated that Ozempic and similar medications may increase the risk of kidney cancer. However, the drugs reportedly lower the risk of more than a dozen other cancers, suggesting their overall benefit may still outweigh the hazards. Additionally, the EMA previously investigated reports of suicidal thoughts associated with semaglutide use, though no definitive causal relationship was established.
The EMA's recommendations will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP) before a final decision is adopted by the European Commission. Novo Nordisk, which was dethroned as Europe's most valuable company earlier this year, has stated its commitment to patient safety and is working with the EMA to update product labels accordingly.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Russia Today
03-07-2025
- Russia Today
Every Dutch person has ‘forever chemicals' in their blood
Every person in the Netherlands has so-called 'forever chemicals' in their blood, often at levels above health safety limits, according to the findings of the first nationwide study on the issue in an EU country, published on Thursday. PFAS, or per- and polyfluoroalkyl substances, are a group of human-made chemicals used in products like plastic food wrappers, non-stick cookware, stain-resistant fabrics, cleaning agents, and personal care items. Due to their durability, they break down extremely slowly and can persist in the environment and living organisms for years, hence the nickname 'forever chemicals.' The survey published on Thursday by the Dutch National Institute for Public Health and the Environment (RIVM), found that 'Everyone in the Netherlands has different types of PFAS in the blood. In almost everyone, the amount of PFAS is higher than the health limit value.' Human exposure typically occurs through contaminated food, drinking water, household products, air, and soil. Studies have linked certain PFAS compounds to health issues such as high cholesterol, infertility, kidney problems, and some cancers. Though their presence does not guarantee illness, the chemicals may impair the immune system, with the severity of effects depending on the level and duration of exposure, as well as individual health conditions, the institute noted. The study analyzed around 1,500 blood samples collected between 2016 and 2017, and RIVM confirmed it is currently examining samples from 2025 to assess recent exposure trends. While PFAS are known for persisting in the body, they can gradually disappear over time, the institute noted, stressing the need to reduce daily intake. Similar studies have been conducted in the US, Canada, and Australia, revealing widespread exposure across various populations.
Russia Today
28-06-2025
- Russia Today
Global cocaine production hits all-time high
Global cocaine production surged to a new record in 2023, accompanied by soaring seizures, growing user numbers, and rising deaths, the UN Office on Drugs and Crime (UNODC) has said. On Thursday, the UNODC released its annual report, warning that a 'new era of global instability' is empowering organized crime and driving drug use to unprecedented levels. The report found that cocaine has become the fastest-growing illicit drug market worldwide. Illegal production skyrocketed to an estimated 3,708 tons in 2023 – up nearly 34% from 2022 – driven largely by expanded coca cultivation and higher yields in Colombia. Use of the drug climbed to an estimated 25 million people in 2023, up from 17 million in 2013. The highest consumption continues to be in North America, Western and Central Europe, and South America, with wastewater data showing sharp rises in European cities. Cocaine seizures in Western and Central Europe surpassed those in North America for the fifth consecutive year. Globally, between 2019 and 2023, the amount of cocaine seized rose by 68%. Drug consumption remains a major issue, with a total of 316 million people using illicit substances, excluding alcohol and tobacco, in 2023, according to the report. The figure accounts for 6% of the global population aged between 15 and 64, compared to 5.2% in 2013. Drug use disorders have a major impact on global health, causing nearly half a million deaths annually and costing 28 million healthy years of life lost worldwide. Yet only one in 12 people with such disorders received any treatment in 2023, the report says. Commenting on the findings, UNODC Executive Director Ghada Waly called for greater investment in prevention, cross-border cooperation, and judicial action to dismantle criminal networks. Cocaine use causes a burst of euphoria and energy, but it is associated with serious health risks, including heart attacks, strokes, respiratory failure, and neurological damage. The drug is also highly addictive, often leading to cycles of binge use and severe withdrawal.
Russia Today
07-06-2025
- Russia Today
Popular weight loss drug could cause sudden blindness – EU's health watchdog
The European Medicines Agency (EMA) has concluded that semaglutide-based medications – including Ozempic, Wegovy, and Rybelsus – increase the risk of a serious eye condition that can lead to sudden vision loss. Following a comprehensive safety review, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) determined that non-arteritic anterior ischemic optic neuropathy (NAION) should be listed as a 'very rare' side effect of semaglutide – the main component of weight-loss and anti-diabetic drugs produced by Novo Nordisk. The EMA's review, initiated in January 2025, analyzed data from clinical trials, post-marketing surveillance, and medical literature. Findings suggest that adults with type 2 diabetes taking semaglutide have approximately twice the risk of developing NAION compared to those not on the medication. On Friday, the EU's health watchdog recommended updating the product information for semaglutide-containing medicines to include NAION as a potential side effect. The 'very rare' classification indicates that the condition may affect up to 1 in 10,000 users. NAION is the second most common cause of optic nerve-related blindness after glaucoma. Patients experiencing sudden vision loss or rapidly worsening eyesight while on semaglutide are advised to seek immediate medical attention and discontinue use if NAION is diagnosed. The Denmark-based company Novo Nordisk owns the patent on semaglutide, a GLP-1 receptor agonist used for managing type 2 diabetes and obesity. It functions by enhancing insulin secretion and promoting a feeling of fullness, thereby aiding in blood sugar control and weight management. A recent study also indicated that Ozempic and similar medications may increase the risk of kidney cancer. However, the drugs reportedly lower the risk of more than a dozen other cancers, suggesting their overall benefit may still outweigh the hazards. Additionally, the EMA previously investigated reports of suicidal thoughts associated with semaglutide use, though no definitive causal relationship was established. The EMA's recommendations will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP) before a final decision is adopted by the European Commission. Novo Nordisk, which was dethroned as Europe's most valuable company earlier this year, has stated its commitment to patient safety and is working with the EMA to update product labels accordingly.
